HeartSciences Posts $3.2M Loss, Signs First US Deals for MyoVista Insights
HSCS has more than doubled off its 52-week low of $1.63.
Summary
HeartSciences reported a fiscal Q1 2027 net loss of $3.2 million with no meaningful revenue, and a shareholders' deficit of $2.0 million as of July 31, 2026. The company signed its first US commercial agreements for the MyoVista Insights platform and was selected as the AI-ECG delivery platform for a major European reference center. Fortitude subscribed for approximately $1.0 million of HeartSciences common stock in August 2026, and the company raised about $1.2 million net from at-the-market sales plus exchanged $200,000 of promissory note principal for shares. Management expects the Fortitude merger to close in Q4 calendar 2026, subject to shareholder approval. The company also recorded a $0.3 million inventory reserve against the MyoVista wavECG device, signaling reduced commitment to that hardware path.
At the time of this announcement, HSCS was trading at $3.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $1.63 to $4.35. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.